Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1247

Shown on this page

Current sort

Live official records

Conditions: Systolic Heart Failure, Respiratory Failure
Interventions: Airvo 3; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 45
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more

Conditions: Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions: NEVA VS; Device
Lead sponsor: Vesalio; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 16
States / cities: Burbank, California • Walnut Creek, California • New Haven, Connecticut + 13 more

Conditions: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier
Interventions: Observational study with patients who may be treated with various disease-modifying therapies; Other
Lead sponsor: The Duchenne Registry; Other
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2072
U.S. locations: 10
States / cities: Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 6 more

Conditions: Hypophosphatemia, Rickets, Hypercalciuria, XLH, HHRH
Interventions: phosphate; Drug
Lead sponsor: Yale University; Other
Eligibility: 13 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
Interventions: Digoxin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: HER2 Negative Breast Cancer
Interventions: Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy; Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: Sun Yat-sen University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
Interventions: Dapagliflozin 10mg; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Heart Failure, Diuretic Resistance
Interventions: Ammonium Chloride, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer
Interventions: Standard of Care; Other
Lead sponsor: Prostate Cancer Clinical Trials Consortium; Other
Eligibility: 21 Years and older · Male only
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 48
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Los Angeles, California + 35 more

Conditions: Recurrent Pregnancy Loss
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 6 more

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Live official records

A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts

Duchenne Electronic Health Record Study

The Impact of Phosphate Metabolism on Healthy Aging

Digoxin In NASH (CODIN)

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Genomic Predictors of Recurrent Pregnancy Loss

About this Yale institution page